* Accelerate Diagnostics Inc AXDX.OQ AXDX.O is expected
to show a rise in quarterly revenue when it reports results on
August 15.
* The Denver Colorado-based company is expected to report
a
7.2% increase in revenue to $3 million from $2.8 million a year
ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for Accelerate
Diagnostics
Inc is for a loss of 28 cents per share. For the same quarter
last year, the company reported a loss of 36 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Accelerate
Diagnostics Inc is $1, below its last closing price of $2.15.
This summary was machine generated August 12 at 21:24 GMT. All
figures in US dollars unless otherwise stated